Mauna Kea (MKEAF) 4.4900 $MKEAF
Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan
PR Newswire - Mon Jul 06, 12:00PM CDT
Mauna Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, announced today it has obtained approval from Japan's Ministry of Health, Labor and Welfare (MHLW) for its unique needle-base Confocal Laser Endomicroscopy solution, the AQ-Flex 19 miniprobe.
Mauna Kea Technologies Announces CE Mark for use of Cellvizio® During Interventional Radiology Procedures
PR Newswire - Tue Jun 09, 12:17PM CDT
-- Key regulatory and product development milestone on the company's application roadmap
Mauna Kea Technologies Announces CE Mark for Use of Cellvizio® in Minimally Invasive Surgery
PR Newswire - Mon May 18, 12:04PM CDT
Mauna Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, announced today CE mark for the use of Cellvizio in minimally invasive laparoscopic surgical indications. This regulatory milestone positions Cellvizio for useful imaging support in a wide range of oncologic surgical procedures, many of which have already been investigated successfully in several clinical studies throughout Europe.
Mauna Kea Technologies Obtains Regulatory Approval for the Commercialization of Cellvizio® in Mexico
PR Newswire - Mon Apr 20, 11:42AM CDT
-- Mexico is the second largest medical device market in Latin America after Brazil
Mauna Kea Technologies Reports Record Attendance at ICCU 2015 and at the Associated Post-graduate Course on Endomicroscopy
PR Newswire - Wed Apr 15, 11:00AM CDT
-- 300 physicians and surgeons gathered in Lisbon at the International Conference of Cellvizio Users to discuss advancements and benefits of endomicroscopy in multiple medical and surgical indications
Grenoble University Hospital First Hospital in France to set up a Multidisciplinary Optical Biopsy Program With the Cellvizio Endomicroscopy Platform
PR Newswire - Tue Mar 31, 12:21PM CDT
Mauna Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced the set-up of an optical biopsy program at the CHU de Grenoble (university hospital center). The CHU de Grenoble is now the first hospital in France to propose to its gastroenterology, interventional pulmonology and urology patients an innovative platform for clinical research and a higher standard of care thanks to the endomicroscopy technology developed by Mauna Kea Technologies.
Mauna Kea Technologies Announces Publication of Confirmation Data on the Value of Endomicroscopy for the Characterization of Pancreatic Cystic Neoplasms
PR Newswire - Wed Mar 25, 12:00PM CDT
Investigator-Initiated DETECT Study shows benefits of using Cellvizio to safely differentiate the nature of pancreas cysts with high specificity and accuracy
Baptist Medical Center in Florida Adopts Endomicroscopy with Cellvizio to Improve Care for Patients with Biliary and Pancreatic Diseases
PR Newswire - Mon Mar 23, 2:03PM CDT
Mauna Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced that Baptist Medical Center in Jacksonville, Florida, a leading medical center in the southeastern United States, has adopted the Cellvizio technology platform to perform enhanced procedures in the field of biliary and pancreatic disorders including probe-based confocal laser endomicroscopy (pCLE) and needle-based confocal laser endomicroscopy (nCLE).
Leading 100 Medical Devices/Technology/Supplies Companies of Europe 2015
M2 - Mon Mar 23, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wfwcrh/europe_medical) has announced the addition of the "Europe Medical Devices/Technology/Supplies 100: An Industry Report" report to their offering. Medical technology aims to improve the quality of healthcare provided. Recent advances in this industry globally are focusing on cost reduction, less-invasive treatment options, and reduction in hospital stays and rehabilitation process. Medical technology is a key driver for Europe's economic well-being, providing quality employment, and a substantial contribution to Europe's balance of trade. The European medical technology market is estimated at roughly 100 billion and is the second largest medical technology market after US. It has been growing on average by 4% per annum over the past 6 years. Through its healthcare innovations, the European medical device industry contributes to ensuring sustainable and accessible healthcare systems throughout Europe. With this special industry report, our endeavor is to provide the new investors globally with a complete resourceful research report for familiarizing with the present investment trends of the European companies in the medical industry, which they would find beneficial to pursue for making business decisions in this sector. Report Highlights: - Leading 100 medical devices/technology/supplies companies of Europe - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances among European medical devices/technology/supplies companies - International presence of European medical devices/technology/supplies companies - R&D activities by European medical devices/technology/supplies companies Report Includes Companies Engaged in: - Manufacturing medical equipments providing any medical activity and/or treatment - Manufacturing diagnostic equipments - Manufacturing high-tech medical instruments - Manufacturing life-support medical equipments - Manufacturing research instruments and scientific analytical equipment - Providing software for improving treatments - Providing medical information technology - Manufacturing medical bio-tech products - Providing value-based healthcare services - Manufacturing molecular diagnostic instruments - Manufacturing pacemakers, imaging instruments, dialysis machines and implants, hip and knee replacement medical devices, heart stents, thermal cyclers and mass spectrometers, microarrays and other similar products - Manufacturing and/or selling basic medical and surgical materials (consumables), low-tech items and items used in medical equipment processor or for treating patients - Diagnostic equipment supplies - Medical supplies invasive and medical supplies non invasive - Manufacturing/supplying replaceable lenses for equipments - Manufacturing/supplying any item which needs to be replaced as a function of repeated medical activity or where need for treatments is constant - Manufacturing/supplying surgical and dental instruments, elective laser surgery equipments, orthopedic products, and other such products Companies Mentioned - Ion Beam Applications SA (Belgium) - Kitron ASA (Norway) - LiDCO Group PLC (United Kingdom) - MagForce AG (Germany) - Mauna Kea Technologies SAS (France) - Medica AD Sofia (Bulgaria) - Medicrea International (France) - Medisana AG (Germany) - Mercator Medical SA (Poland) - Nobel Biocare Holding AG (Switzerland) - Omega Diagnostics Group Plc (United Kingdom) - Orthofix International N.V. (Netherlands Antilles) - PuriCore PLC (United Kingdom) - PZ Cormay SA (Poland) - Sorin SpA (Italy) - Stentys (France) - Surgical Innovations Group PLC (United Kingdom) - Technoflex SA (France) - Voxel S.A. (Poland) For more information visit http://www.researchandmarkets.com/research/wf...pe_medical
OFIX: 33.22 (+1.39)
Mauna Kea Technologies Receives Additional CPT® Reimbursement Code in the U.S. Supporting Key Application of Endomicroscopy with Cellvizio in the Biliary Tract
PR Newswire - Tue Mar 17, 1:02PM CDT
Mauna Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced that the American Medical Association (AMA) Editorial Panel has awarded a new CPT Code related to the use of endomicroscopy during endoscopic retrograde cholangiopancreatography (ERCP) procedures to enable physicians to diagnose health problems in the biliary tract including diagnosis of biliary strictures and the presence of biliary cancer. More than 500,000 ECRPs are completed annually in the United States.
Mauna Kea Technologies Announces Acceleration of Installations and Use of Cellvizio Endomicroscopy Platform in Japan
PR Newswire - Wed Mar 11, 6:46PM CDT
Technology highlighted in first-ever Japanese live demonstration during the 14th Yokohama International Endoscopy Conference.
Mauna Kea Technologies Announces Positive Results from FOCUS Pivotal Clinical Trial on Use of Confocal Laser Endomicroscopy in Biliary Cancer Detection
PR Newswire - Tue Jan 27, 10:45AM CST
Results published in peer-reviewed journal Gastrointestinal Endoscopy accompanied by editorial noting that the study "pushes the boundaries of diagnosis in indeterminate biliary strictures"
Mauna Kea Technologies Announces Publication of Consensus Report Based on Clinical Evidence on Use of Confocal Laser Endomicroscopy in Gastroenterology
PR Newswire - Tue Jan 20, 10:45AM CST
Mauna Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced publication of the first consensus recommendations on the clinical use of probe-based confocal laser endomicroscopy (pCLE) in gastrointestinal applications, by the peer-reviewed journal United European Gastroenterology. The recommendations were presented in an article entitled: "Use of probe-based confocal laser endomicroscopy (pCLE) in gastrointestinal applications: a consensus report based on clinical evidence", authored by 26 international experts in gastroenterology and confocal laser endomicroscopy.
Mauna Kea Technologies: Editorial Highlighting Advantages of Needle-based Endomicroscopy for Characterization of Pancreatic Cysts Published in Endoscopy
PR Newswire - Wed Jan 14, 11:30AM CST
-- Editorial accompanies publication of CONTACT 1 Study results showing that needle-based confocal laser endomicroscopy with Cellvizio able to confirm benign serous cystadenomas with 100% specificity.
Mauna Kea Technologies Announces 2014 Sales Growth of +10% to EUR 11.0m
PR Newswire - Wed Jan 07, 11:00AM CST
-- Strong growth in Asia-Pacific region: +52%
Mauna Kea Technologies and Siemens Announce Joint Effort to Evaluate the Use of Cellvizio in Interventional Radiology
PR Newswire - Mon Nov 03, 12:27PM CST
Mauna Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the unique trans-disciplinary optical biopsy platform, today announced a new collaboration with Siemens Healthcare to evaluate the clinical benefits of Cellvizio® in interventional radiology procedures. Cellvizio's needle-based optical biopsy technology will be used in combination with Siemens Angiography & Interventional X-ray (AX) and Computed Tomography (CT) imaging systems in two clinical studies taking place at the Hôpital Européen Georges Pompidou (HEGP) in Paris and the University Hospital in Strasbourg, France.
Surgeons at Coliseum Northside Hospital Among First in Nation to use Endomicroscopic Imaging With Cellvizio to Identify Esophageal Disease Prior to Anti-Reflux Surgery
PR Newswire - Tue Oct 28, 11:45AM CDT
Mauna Kea Technologies (Euronext : MKEA FR0010609263) and Coliseum Northside Hospital, an HCA hospital, today announced that surgeons at Coliseum Northside Hospital are among the first in the U.S. to use an advanced endomicroscopy technology called Cellvizio to identify pre-cancerous and cancerous cells in patients gastroesophageal reflux disease (GERD). According to guidelines established by the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), it is important to take steps to identify and treat pre-cancerous or cancerous cells prior to anti-reflux surgery.
Mauna Kea Technologies: Physicians Using Optical Biopsy with Cellvizio Discover a New Diagnostic Criterion Specific for Benign Pancreatic Cysts and Invisible with Other Imaging Technologies
Business Wire - Tue Oct 21, 11:51AM CDT
--Findings from prospective multicenter CONTACT 1 study published in peer-reviewed journal Endoscopy.
Mauna Kea Technologies : Success and Strong Attendance for Cellvizio at the Annual Chinese Conference of Digestive Endoscopy, Ccdd 2014
Business Wire - Mon Oct 13, 11:07AM CDT
--Several speakers presented the clinical benefits of Cellvizio then demonstrated it in a live procedure performed in front of an audience of over 2,500 Chinese physicians
Mauna Kea Technologies Announces That the French High Authority for Health Has Given a Favorable Opinion for the Inscription of Optical Endomicroscopy for Barrett's Esophagus on the List of Reimbursable Procedures
Business Wire - Mon Oct 13, 10:59AM CDT
Regulatory News:
Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan
PR Newswire - Mon Jul 06, 12:00PM CDT
Mauna Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, announced today it has obtained approval from Japan's Ministry of Health, Labor and Welfare (MHLW) for its unique needle-base Confocal Laser Endomicroscopy solution, the AQ-Flex 19 miniprobe.
Mauna Kea Technologies Announces CE Mark for use of Cellvizio® During Interventional Radiology Procedures
PR Newswire - Tue Jun 09, 12:17PM CDT
-- Key regulatory and product development milestone on the company's application roadmap
Mauna Kea Technologies Announces CE Mark for Use of Cellvizio® in Minimally Invasive Surgery
PR Newswire - Mon May 18, 12:04PM CDT
Mauna Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, announced today CE mark for the use of Cellvizio in minimally invasive laparoscopic surgical indications. This regulatory milestone positions Cellvizio for useful imaging support in a wide range of oncologic surgical procedures, many of which have already been investigated successfully in several clinical studies throughout Europe.
Mauna Kea Technologies Obtains Regulatory Approval for the Commercialization of Cellvizio® in Mexico
PR Newswire - Mon Apr 20, 11:42AM CDT
-- Mexico is the second largest medical device market in Latin America after Brazil
Mauna Kea Technologies Reports Record Attendance at ICCU 2015 and at the Associated Post-graduate Course on Endomicroscopy
PR Newswire - Wed Apr 15, 11:00AM CDT
-- 300 physicians and surgeons gathered in Lisbon at the International Conference of Cellvizio Users to discuss advancements and benefits of endomicroscopy in multiple medical and surgical indications
Grenoble University Hospital First Hospital in France to set up a Multidisciplinary Optical Biopsy Program With the Cellvizio Endomicroscopy Platform
PR Newswire - Tue Mar 31, 12:21PM CDT
Mauna Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced the set-up of an optical biopsy program at the CHU de Grenoble (university hospital center). The CHU de Grenoble is now the first hospital in France to propose to its gastroenterology, interventional pulmonology and urology patients an innovative platform for clinical research and a higher standard of care thanks to the endomicroscopy technology developed by Mauna Kea Technologies.
Mauna Kea Technologies Announces Publication of Confirmation Data on the Value of Endomicroscopy for the Characterization of Pancreatic Cystic Neoplasms
PR Newswire - Wed Mar 25, 12:00PM CDT
Investigator-Initiated DETECT Study shows benefits of using Cellvizio to safely differentiate the nature of pancreas cysts with high specificity and accuracy
Baptist Medical Center in Florida Adopts Endomicroscopy with Cellvizio to Improve Care for Patients with Biliary and Pancreatic Diseases
PR Newswire - Mon Mar 23, 2:03PM CDT
Mauna Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced that Baptist Medical Center in Jacksonville, Florida, a leading medical center in the southeastern United States, has adopted the Cellvizio technology platform to perform enhanced procedures in the field of biliary and pancreatic disorders including probe-based confocal laser endomicroscopy (pCLE) and needle-based confocal laser endomicroscopy (nCLE).
Leading 100 Medical Devices/Technology/Supplies Companies of Europe 2015
M2 - Mon Mar 23, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wfwcrh/europe_medical) has announced the addition of the "Europe Medical Devices/Technology/Supplies 100: An Industry Report" report to their offering. Medical technology aims to improve the quality of healthcare provided. Recent advances in this industry globally are focusing on cost reduction, less-invasive treatment options, and reduction in hospital stays and rehabilitation process. Medical technology is a key driver for Europe's economic well-being, providing quality employment, and a substantial contribution to Europe's balance of trade. The European medical technology market is estimated at roughly 100 billion and is the second largest medical technology market after US. It has been growing on average by 4% per annum over the past 6 years. Through its healthcare innovations, the European medical device industry contributes to ensuring sustainable and accessible healthcare systems throughout Europe. With this special industry report, our endeavor is to provide the new investors globally with a complete resourceful research report for familiarizing with the present investment trends of the European companies in the medical industry, which they would find beneficial to pursue for making business decisions in this sector. Report Highlights: - Leading 100 medical devices/technology/supplies companies of Europe - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances among European medical devices/technology/supplies companies - International presence of European medical devices/technology/supplies companies - R&D activities by European medical devices/technology/supplies companies Report Includes Companies Engaged in: - Manufacturing medical equipments providing any medical activity and/or treatment - Manufacturing diagnostic equipments - Manufacturing high-tech medical instruments - Manufacturing life-support medical equipments - Manufacturing research instruments and scientific analytical equipment - Providing software for improving treatments - Providing medical information technology - Manufacturing medical bio-tech products - Providing value-based healthcare services - Manufacturing molecular diagnostic instruments - Manufacturing pacemakers, imaging instruments, dialysis machines and implants, hip and knee replacement medical devices, heart stents, thermal cyclers and mass spectrometers, microarrays and other similar products - Manufacturing and/or selling basic medical and surgical materials (consumables), low-tech items and items used in medical equipment processor or for treating patients - Diagnostic equipment supplies - Medical supplies invasive and medical supplies non invasive - Manufacturing/supplying replaceable lenses for equipments - Manufacturing/supplying any item which needs to be replaced as a function of repeated medical activity or where need for treatments is constant - Manufacturing/supplying surgical and dental instruments, elective laser surgery equipments, orthopedic products, and other such products Companies Mentioned - Ion Beam Applications SA (Belgium) - Kitron ASA (Norway) - LiDCO Group PLC (United Kingdom) - MagForce AG (Germany) - Mauna Kea Technologies SAS (France) - Medica AD Sofia (Bulgaria) - Medicrea International (France) - Medisana AG (Germany) - Mercator Medical SA (Poland) - Nobel Biocare Holding AG (Switzerland) - Omega Diagnostics Group Plc (United Kingdom) - Orthofix International N.V. (Netherlands Antilles) - PuriCore PLC (United Kingdom) - PZ Cormay SA (Poland) - Sorin SpA (Italy) - Stentys (France) - Surgical Innovations Group PLC (United Kingdom) - Technoflex SA (France) - Voxel S.A. (Poland) For more information visit http://www.researchandmarkets.com/research/wf...pe_medical
OFIX: 33.22 (+1.39)
Mauna Kea Technologies Receives Additional CPT® Reimbursement Code in the U.S. Supporting Key Application of Endomicroscopy with Cellvizio in the Biliary Tract
PR Newswire - Tue Mar 17, 1:02PM CDT
Mauna Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced that the American Medical Association (AMA) Editorial Panel has awarded a new CPT Code related to the use of endomicroscopy during endoscopic retrograde cholangiopancreatography (ERCP) procedures to enable physicians to diagnose health problems in the biliary tract including diagnosis of biliary strictures and the presence of biliary cancer. More than 500,000 ECRPs are completed annually in the United States.
Mauna Kea Technologies Announces Acceleration of Installations and Use of Cellvizio Endomicroscopy Platform in Japan
PR Newswire - Wed Mar 11, 6:46PM CDT
Technology highlighted in first-ever Japanese live demonstration during the 14th Yokohama International Endoscopy Conference.
Mauna Kea Technologies Announces Positive Results from FOCUS Pivotal Clinical Trial on Use of Confocal Laser Endomicroscopy in Biliary Cancer Detection
PR Newswire - Tue Jan 27, 10:45AM CST
Results published in peer-reviewed journal Gastrointestinal Endoscopy accompanied by editorial noting that the study "pushes the boundaries of diagnosis in indeterminate biliary strictures"
Mauna Kea Technologies Announces Publication of Consensus Report Based on Clinical Evidence on Use of Confocal Laser Endomicroscopy in Gastroenterology
PR Newswire - Tue Jan 20, 10:45AM CST
Mauna Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced publication of the first consensus recommendations on the clinical use of probe-based confocal laser endomicroscopy (pCLE) in gastrointestinal applications, by the peer-reviewed journal United European Gastroenterology. The recommendations were presented in an article entitled: "Use of probe-based confocal laser endomicroscopy (pCLE) in gastrointestinal applications: a consensus report based on clinical evidence", authored by 26 international experts in gastroenterology and confocal laser endomicroscopy.
Mauna Kea Technologies: Editorial Highlighting Advantages of Needle-based Endomicroscopy for Characterization of Pancreatic Cysts Published in Endoscopy
PR Newswire - Wed Jan 14, 11:30AM CST
-- Editorial accompanies publication of CONTACT 1 Study results showing that needle-based confocal laser endomicroscopy with Cellvizio able to confirm benign serous cystadenomas with 100% specificity.
Mauna Kea Technologies Announces 2014 Sales Growth of +10% to EUR 11.0m
PR Newswire - Wed Jan 07, 11:00AM CST
-- Strong growth in Asia-Pacific region: +52%
Mauna Kea Technologies and Siemens Announce Joint Effort to Evaluate the Use of Cellvizio in Interventional Radiology
PR Newswire - Mon Nov 03, 12:27PM CST
Mauna Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the unique trans-disciplinary optical biopsy platform, today announced a new collaboration with Siemens Healthcare to evaluate the clinical benefits of Cellvizio® in interventional radiology procedures. Cellvizio's needle-based optical biopsy technology will be used in combination with Siemens Angiography & Interventional X-ray (AX) and Computed Tomography (CT) imaging systems in two clinical studies taking place at the Hôpital Européen Georges Pompidou (HEGP) in Paris and the University Hospital in Strasbourg, France.
Surgeons at Coliseum Northside Hospital Among First in Nation to use Endomicroscopic Imaging With Cellvizio to Identify Esophageal Disease Prior to Anti-Reflux Surgery
PR Newswire - Tue Oct 28, 11:45AM CDT
Mauna Kea Technologies (Euronext : MKEA FR0010609263) and Coliseum Northside Hospital, an HCA hospital, today announced that surgeons at Coliseum Northside Hospital are among the first in the U.S. to use an advanced endomicroscopy technology called Cellvizio to identify pre-cancerous and cancerous cells in patients gastroesophageal reflux disease (GERD). According to guidelines established by the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), it is important to take steps to identify and treat pre-cancerous or cancerous cells prior to anti-reflux surgery.
Mauna Kea Technologies: Physicians Using Optical Biopsy with Cellvizio Discover a New Diagnostic Criterion Specific for Benign Pancreatic Cysts and Invisible with Other Imaging Technologies
Business Wire - Tue Oct 21, 11:51AM CDT
--Findings from prospective multicenter CONTACT 1 study published in peer-reviewed journal Endoscopy.
Mauna Kea Technologies : Success and Strong Attendance for Cellvizio at the Annual Chinese Conference of Digestive Endoscopy, Ccdd 2014
Business Wire - Mon Oct 13, 11:07AM CDT
--Several speakers presented the clinical benefits of Cellvizio then demonstrated it in a live procedure performed in front of an audience of over 2,500 Chinese physicians
Mauna Kea Technologies Announces That the French High Authority for Health Has Given a Favorable Opinion for the Inscription of Optical Endomicroscopy for Barrett's Esophagus on the List of Reimbursable Procedures
Business Wire - Mon Oct 13, 10:59AM CDT
Regulatory News:
